Skip to main content

Advertisement

SpringerLink
Log in

Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study

  • Original Paper
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Purpose

To assess incidence rate, risk factors and susceptibility patterns associated with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae in community-acquired urinary tract infections (CA-UTIs).

Methods

A prospective, case-control study was conducted at a tertiary teaching hospital from Jan 2015 to Dec 2016. The results of microbiology cultures were initially screened to include only patients with positive E. coli or K. pneumoniae urine cultures. Afterwards, clinical symptoms were assessed to confirm the UTI. To investigate the risk factors, patients with a positive urine culture for ESBL-producing isolates were assigned as cases, while patients with non-ESBL were assigned as controls.

Results

Out of 591 patients included in this study, 57.5% (n = 340) were included in the control group and 42.5% (n = 251) were in the case group. The incidence rate of ESBL-producing isolates was 3.465 cases per 1000-patient hospital admissions. Male gender (OR = 1.856, 95% CI = 1.192–2.889, p = 0.006), pediatrics (OR = 1.676, 95% CI = 1.117–2.517, p = 0.013), patients with comorbidity (OR = 1.542, 95% CI = 1.029–2.312, p = 0.036) and UTI in the previous 12 months (OR = 1.705, 95% CI = 1.106–2.628, p = 0.016) were independently associated with a higher risk of infection. The resistance rate for most commonly prescribed antibiotics was high.

Conclusions

Our results suggest that the incidence of ESBL producers among CA-UTIs is high. Male gender, pediatrics, comorbidity and UTI in the previous 12 months were associated with a higher risk for infection. Continuous surveillance and prudent antibiotic use by healthcare professionals are important factors for effective control of ESBL associated infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333–40. https://doi.org/10.1007/s15010-011-0132-6.

    Article  PubMed  CAS  Google Scholar 

  2. Khadri H, Alzohairy M. High prevalence of multi-drug- resistance (MDR) and extended spectrum-lactamases (ESBL) producing bacteria among community-acquired urinary tract infections (CAUTI). J Bacteriol Res. 2009;1:105–10.

    CAS  Google Scholar 

  3. Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011;43:339–43. https://doi.org/10.3109/00365548.2011.553241.

    Article  PubMed  CAS  Google Scholar 

  4. Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, et al. Rise of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47:399–405. https://doi.org/10.1016/j.jmii.2013.05.006.

    Article  PubMed  Google Scholar 

  5. Kung CH, Ku WW, Lee CH, Fung CP, Kuo SC, Chen TL, et al. Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study. J Microbiol Immunol Infect. 2015;48:168–74. https://doi.org/10.1016/j.jmii.2013.08.006.

    Article  PubMed  Google Scholar 

  6. Nimri L. Community-acquired urinary tract infections in a rural area in Jordan: predominant uropathogens, and their antimicrobial resistance. Webmed Central Microbiol. 2010;1:1–10.

    Google Scholar 

  7. Ozcakar ZB, Yalcinkaya F, Kavaz A, Kadioglu G, Elhan AH, Aysev D, et al. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change—clinical pattern does not. Acta Paediatr. 2011;100:e61–4. https://doi.org/10.1111/j.1651-2227.2011.02262.x.

    Article  PubMed  Google Scholar 

  8. Chen PC, Chang LY, Lu CY, Shao PL, Tsai IJ, Tsau YK, et al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J Microbiol Immunol Infect. 2014;47:478–83. https://doi.org/10.1016/j.jmii.2013.07.011.

    Article  PubMed  CAS  Google Scholar 

  9. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66. https://doi.org/10.1016/S1473-3099(08)70041-0.

    Article  PubMed  CAS  Google Scholar 

  10. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–6.

    Article  PubMed  CAS  Google Scholar 

  11. Tratselas A, Iosifidis E, Ioannidou M, Saoulidis S, Kollios K, Antachopoulos C, et al. Outcome of urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J. 2011;30:707–10. https://doi.org/10.1097/INF.0b013e31820d7ec4.

    Article  PubMed  Google Scholar 

  12. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Dueñas-Laita A, Pérez-Castrillón JL. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66:891–6. https://doi.org/10.1111/j.1742-1241.2012.02991.x.

    Article  PubMed  CAS  Google Scholar 

  13. Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D. Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013;163:1417–21. https://doi.org/10.1016/j.jpeds.2013.06.078.

    Article  PubMed  Google Scholar 

  14. Goulenok T, Ferroni A, Bille E, Lecuyer H, Join-Lambert O, Descamps P, et al. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect. 2013;84:294–9. https://doi.org/10.1016/j.jhin.2013.04.018.

    Article  PubMed  CAS  Google Scholar 

  15. Moor CT, Roberts SA, Simmons G, Briggs S, Morris AJ, Smith J, et al. Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect. 2008;68:355–62. https://doi.org/10.1016/j.jhin.2008.02.003.

    Article  PubMed  CAS  Google Scholar 

  16. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147–51. https://doi.org/10.1111/j.1469-0691.2009.02941.x.

    Article  PubMed  CAS  Google Scholar 

  17. Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtas M, Gurcuoglu E, et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother. 2008;20:581–5. https://doi.org/10.1179/joc.2008.20.5.581.

    Article  PubMed  CAS  Google Scholar 

  18. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-Third Informational Supplement. Document M100-S23. Wayne: PA; 2013.

  19. Al-Bakri AG, Bustanji Y, Yousef AM. Community consumption of antibacterial drugs within the Jordanian population: sources, patterns and appropriateness. Int J Antimicrob Agents. 2005;26:389–95.

    Article  PubMed  CAS  Google Scholar 

  20. Kader AA, Angamuthu K. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J. 2005;26:956–9.

    PubMed  Google Scholar 

  21. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–90. https://doi.org/10.1086/604713.

    Article  PubMed  Google Scholar 

  22. Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern—a hospital based cross sectional study. BMC Infect Dis. 2017;17:138. https://doi.org/10.1186/s12879-017-2250-y.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Hayajneh WA, Hajj A, Hulliel F, Sarkis DK, Irani-Hakimeh N, Kazan L, et al. Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011–2013. Int J Infect Dis. 2015;35:56–61. https://doi.org/10.1016/j.ijid.2015.04.011.

    Article  PubMed  CAS  Google Scholar 

  24. Topaloglu R, Er I, Dogan BG, Bilginer Y, Ozaltin F, Besbas N, et al. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr Nephrol. 2010;25:919–25. https://doi.org/10.1007/s00467-009-1431-3.

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by a grant from Deanship of Research at Jordan University of Science and Technology, Irbid, Jordan.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan

    Basima A. Almomani, Abeer M. Ayoub & Mera A. Ababneh

  2. Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan

    Wail A. Hayajneh & Miral A. Al Momani

  3. Department of Pediatrics and Neonatology, King Abdullah University Hospital, Irbid, Jordan

    Wail A. Hayajneh & Miral A. Al Momani

Authors
  1. Basima A. Almomani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wail A. Hayajneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abeer M. Ayoub
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mera A. Ababneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miral A. Al Momani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basima A. Almomani.

Ethics declarations

Conflict of interest

All authors report no conflicts of interest relevant to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almomani, B.A., Hayajneh, W.A., Ayoub, A.M. et al. Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study. Infection 46, 495–501 (2018). https://doi.org/10.1007/s15010-018-1148-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-018-1148-y

Keywords

Search

Navigation